articleThe LancetJun 1, 2011Closed access

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Cardiff University · Medical Research Council · +8 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

967
total citations
FWCI
52.09
Percentile
100%
References
25
Citations per year

Authors

21

Topics & keywords

Keywords
  • Cetuximab
  • Medicine
  • KRAS
  • Oxaliplatin
  • Internal medicine
  • Colorectal cancer
  • Capecitabine
  • Oncology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding